Thank you, Madam Chair.
You've presented a sort of Catch-22 situation in terms of getting pharma to put in, say, 50% of the money, not filing patents and working in those unknown areas we talked about. But about the unintended consequence of pharma, which puts in that chunk of money, saying it owns this information and is not going to share it with anybody else? That is where my thinking is going. Instead of opening up that information so everyone can see it and benefit from it, what we're doing is selling information to the highest bidder who then would patent it, own it, and go ahead and do it.